Global Mycoplasma Testing Market in terms of revenue was estimated to be worth $689 million in 2020 and is poised to reach $1,095 million by 2025, growing at a CAGR of 9.7% from 2020 to 2025. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The global market's growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical and biotechnology industries, and rising pharmaceutical R & D activities and investments.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136509856
Browse in-depth TOC on “Mycoplasma Testing Market”
111 – Tables
37 – Figures
154 – Pages
Key Market Players
The major players operating in this market are Thermo Fisher Scientific, Inc. (US), Charles River Laboratories International, Inc. (US), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), American Type Culture Collection (US), Bionique Testing Laboratories, Inc. (US), InvivoGen (US), PromoCell GmbH (Germany), Biological Industries Israel Beit Haemek Ltd. (Israel), Creative Bioarray (US), Mycoplasma Experience (UK), Norgen Biotek Corp. (Canada), Agilent Technologies (US), Biotools B & M Labs, S.A. (Spain), Eurofins Scientific (Luxembourg), GeneCopoeia, Inc. (US), GenBio (Canada), Minerva Biolabs GmbH (Germany), Meridian Bioscience, Inc. (US), Sartorius AG (Germany), Savyon Diagnostics (Israel), Nelson Laboratories Fairfield, Inc. (US), Clongen Laboratories, LLC (US), and ScienCell Research Laboratories, Inc. (Canada).
Drivers: Growing concerns over cell culture contamination
Cell culture contamination is the most common problem encountered in cell culture laboratories. Cell culture contaminants are divided into two main categories, namely, chemical contaminants and biological contaminants. Chemical contaminants include impurities in media, sera, water, endotoxins, plasticizers, and detergents, while biological contaminants include bacteria, mold, yeast, viruses, and mycoplasma as cross-contamination by other cell lines. For contamination detection, various tests, including mycoplasma testing, are used.
Opportunities: Globalization of clinical trials and R&D and harmonization of regulations resulting in increased outsourcing
The primary reasons pharmaceutical and biopharmaceutical companies are opting for outsourcing clinical trials and R&D are cost efficiency, easy patient recruitment, reduction in operating costs, and less-stringent regulatory frameworks than the US and Western Europe. Besides reducing costs, sponsors attribute improved quality and reduction in the time to market as major drivers for outsourcing their business functions to CROs, CDMOs, and CMOs. Hence, many pharmaceutical and biotechnology companies and academic institutes opt to outsource functions like manufacturing, clinical trial management, R&D, and drug discovery to CROs.
Challenges: High degree of consolidation acts as an entry barrier for new entrants
The top players in this market are large and well-established and enjoy a high degree of brand loyalty. New entrants in this market compete with existing players and set themselves apart by developing innovative product offerings. The high degree of consolidation acts as a major entry barrier for new entrants, which in turn, is expected to restrict investments and thus slow down the growth potential of this market.
The global mycoplasma testing markets growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical and biotechnology industries, and rising pharmaceutical R & D activities and investments.
Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=136509856
The assays, kits, & reagents products segment accounted for the largest share of the mycoplasma testing market, by product & service segment, in 2019
The mycoplasma testing market is segmented into assays, kits, & reagents; instruments; and services based on product & service. In 2019, the assays, kits, & reagents segment accounted for this markets largest share. The frequent purchase of these consumables compared to instruments and the increasing use of kit-based techniques for mycoplasma testing are the essential factors driving this market segments growth.
Cell line testing segment to register the highest growth rate during the forecast period
Based on application, the mycoplasma testing market is segmented into cell line testing, virus testing, and end-of-production cell testing. In 2019, the cell line testing segment accounted for the largest share of this market. Factors such as the rapid growth in the biopharmaceutical industry and the increasing demand for monoclonal antibodies drive this market segments growth.
Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=136509856
Recent Developments:
- In July 2020, Roche Diagnostics launched Cobas 6800, a fully automated system in India.
- In July 2020, Creative Bioarray launched a full range of cell-based services
- In January 2020, Charles River Laboratories (US) acquired HemaCare Corporation (US)
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
